Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice
Alexandra Schäfer, Timothy P. Sheahan(University of North Carolina at Chapel Hill), David R. Martinez(University of North Carolina at Chapel Hill), Ralph S. Baric(University of North Carolina at Chapel Hill), Kendra L. Gully(University of North Carolina at Chapel Hill), Raju Subramanian(Gilead Sciences (United States)), Joy Y. Feng(Gilead Sciences (United States)), Darius Babusis(Gilead Sciences (United States)), Roy Bannister(Gilead Sciences (United States)), Blake J. Bleier(Gilead Sciences (United States)), Tomáš Cihlář(Gilead Sciences (United States)), Fernando R. Moreira(University of North Carolina at Chapel Hill), Venice Du Pont(Gilead Sciences (United States)), Kimberly T. Barrett(Gilead Sciences (United States)), Stephanie A. Montgomery(University of North Carolina at Chapel Hill), Jennifer Tang(Gilead Sciences (United States)), John P. Bilello(Global Vaccines (United States)), John J. Won(University of North Carolina at Chapel Hill), Rao Kalla(Gilead Sciences (United States)), Eisuke Murakami(Gilead Sciences (United States)), Ariane J. Brown(University of North Carolina at Chapel Hill), Kwon Soo Chun(Gilead Sciences (United States)), Richard L. Mackman(Gilead Sciences (United States))
Cited by 24
Related Papers
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
|Nature Communications|2020|1.8k
Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group
|Journal of Virology|2013|1.3k